泰它西普治疗SLE合并抗磷脂抗体综合征患者的疗效观察

The Efficacy of Telitacicept in the Treatment of Patients with Systemic Lupus Erythematosus Combined with Antiphospholipid Syndrome

目的:本研究旨在评估泰它西普(Telitacicept, TA)、贝利尤单抗(Belimumab, BEL)与传统治疗在系统性红斑狼疮(SLE)合并抗磷脂抗体综合征(APS)患者中的临床效果与安全性。方法:通过随机分配30名SLE-APS患者到TA组、BEL组及传统治疗组,比较治疗3个月及6个月后的SLEDAI-2000评分、外周血抗ds-DNA、外周血BLYS水平、外周血APRIL水平、抗磷脂抗体水平及B、T淋巴细胞绝对值变化。结果:治疗后TA组与传统治疗组相比,在SLEDAI-2000评分、外周血抗ds-DNA、外周血β2GPI-IgG、B淋巴细胞绝对计数以及外周血BLYS水平、外周血APRIL水平方面差异均有统计学意义(P β2GPI-IgG、外周血APRIL水平方面也显示出统计学差异(P < 0.05)。三组患者的不良反应差异无统计学意义。结论:泰它西普对于SLE-APS患者具有良好的临床疗效,为SLE-APS个体化治疗策略提供了新选择。

Objective: This study aimed to evaluate the clinical efficacy and safety of telitacicept (TA), belimumab (BEL), and conventional therapy in patients with systemic lupus erythematosus (SLE) combined with antiphospholipid syndrome (APS). Methods: Thirty SLE-APS patients were randomly assigned to the TA group, BEL group, and conventional treatment group. The changes in SLEDAI-2000 scores, peripheral blood anti-ds-DNA, peripheral blood BLYS levels, peripheral blood APRIL levels, antiphospholipid antibody levels, and absolute counts of B and T lymphocytes were compared after 3 and 6 months of treatment. Results: After treatment, there were statistically significant differences in the SLEDAI-2000 scores, peripheral blood anti-ds-DNA, peripheral blood β2GPI-IgG, absolute count of B lymphocytes, peripheral blood BLYS levels, and peripheral blood APRIL levels between the TA group and the conventional treatment group (P β2GPI-IgG and peripheral blood APRIL levels when compared with the BEL group (P < 0.05). There was no statistical difference in adverse reactions among the three groups. Conclusion: Telitacicept has good clinical efficacy in patients with SLE-APS, providing a new option for individualized treatment strategies for SLE-APS.